Skip to main content
Clinical Trials/NCT04122950
NCT04122950
Terminated
N/A

Exergaming to Increase Physical Activity in Overweight/Obese Children and Adolescents

Norwegian University of Science and Technology1 site in 1 country6 target enrollmentFebruary 24, 2020
ConditionsObesity

Overview

Phase
N/A
Intervention
Not specified
Conditions
Obesity
Sponsor
Norwegian University of Science and Technology
Enrollment
6
Locations
1
Primary Endpoint
Daily time physical activity (moderate, vigorous and very vigorous)
Status
Terminated
Last Updated
4 years ago

Overview

Brief Summary

The primary purpose of this study is to examine the effects of regular exergaming for 8 weeks in 24 overweight/obese children and adolescents (10-17 years) on maximal aerobic fitness (VO2max) and physical activity levels measured before and after (8 weeks) intervention period, and in addition at follow-up (12 weeks). We also wish to investigate the effects on markers of cardio metabolic health and body composition, measured at baseline, 8 weeks and 12 weeks follow-up.

Also, the participants gaming frequency will be registered throughout the 8 week period, as well as during the follow-up between 8 and 12 weeks. Aim of this study is to investigate if access to this game can provide health benefits for overweight/obese children and adolescents.

Registry
clinicaltrials.gov
Start Date
February 24, 2020
End Date
March 28, 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Defined as overweight/obese for age and sex
  • Able to ride a bike for up to 60 minutes

Exclusion Criteria

  • Known cardiovascular disease
  • Taking beta-blockers or anti-arrhythmic drugs
  • Other diseases that restrict them from doing High-Intensity Training

Outcomes

Primary Outcomes

Daily time physical activity (moderate, vigorous and very vigorous)

Time Frame: 12 weeks

Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period and at 12 weeks.

Secondary Outcomes

  • Daily time in very vigorous intensity activity (>9.0 metabolic equivalents = METs)(8 and 12 weeks)
  • Bioelectrical impedance(8 and 12 weeks)
  • Fasting triglycerides, LDL-, HDL- and Total cholesterol, as blood marker of cardiometabolic health(8 and 12 weeks)
  • Daily average energy expenditure(8 and 12 weeks)
  • Daily average number of steps(8 and 12 weeks)
  • Daily time in sedentary activity (< 3.0 metabolic equivalents = METs)(8 and 12 weeks)
  • glucose response to a 2 hour glucose tolerance test, as blood marker of cardiometabolic health(8 and 12 weeks)
  • VO2max(8 and 12 weeks)
  • Daily time in moderate intensity activity (3.0-6.0 metabolic equivalents = METs)(8 and 12 weeks)
  • Daily average total physical activity duration(8 and 12 weeks)
  • Daily time in vigorous intensity activity(8 and 12 weeks)
  • Blood Pressure(8 and 12 weeks)
  • Fasting circulating glucose, as blood marker of cardiometabolic health(8 and 12 weeks)
  • Circulating insulin concentration, as blood marker of cardiometabolic health(8 and 12 weeks)
  • Daily time physical activity (moderate, vigorous and very vigorous)(8 weeks)

Study Sites (1)

Loading locations...

Similar Trials